8/29/2019 9:21:06 AM
Natera Appoints Rowan Chapman To Its Board
5/9/2019 4:24:34 PM
Natera Q1 Loss/share $0.54 Vs. Loss $0.61 Year Ago
5/6/2019 11:57:39 AM
FDA Grants Breakthrough Device Designation To Natera's Signatera Test
4/17/2019 11:44:59 PM
Natera Announces Pricing Of Follow-On Offering Of 5.26 Mln Shares At $19/Shr
4/10/2019 8:05:00 AM
Natera Plans To Commercialize Tumor Whole Exome Sequencing From Plasma
3/26/2019 8:09:44 AM
Natera To Partner With AMAL Therapeutics On Clinical Trial Focused On Stage IV Colorectal Cancer
3/12/2019 4:19:01 PM
Natera Q4 Loss/share $0.51 Vs. Loss $0.90 Year Ago
3/11/2019 6:07:46 AM
Natera And BGI Genomics Announce $50 Mln Partnership To Commercialize Signatera Oncology Test In China
2/1/2019 7:31:35 AM
Natera Announces Partnership With Thermo Fisher Scientific's One Lambda Brand
1/7/2019 8:18:22 AM
Natera Reports Publication Of Kidney Transplant Validation Study
1/2/2019 4:03:49 PM
Natera Appoints Steve Chapman As CEO
9/13/2018 1:26:37 PM
Natera Signs Agreement With Bristol-Myers Squibb
7/12/2018 8:04:10 AM
Natera Prices Public Offering Of 4.50 Mln Shares At $20/Shr